KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Net Income (2016 - 2025)

Historic Net Income for Emergent BioSolutions (EBS) over the last 16 years, with Q3 2025 value amounting to $51.2 million.

  • Emergent BioSolutions' Net Income fell 5540.07% to $51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.9 million, marking a year-over-year increase of 13635.06%. This contributed to the annual value of -$190.6 million for FY2024, which is 7493.75% up from last year.
  • Per Emergent BioSolutions' latest filing, its Net Income stood at $51.2 million for Q3 2025, which was down 5540.07% from -$12.0 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Net Income ranged from a high of $177.9 million in Q4 2021 and a low of -$283.1 million during Q2 2024
  • Moreover, its 5-year median value for Net Income was -$31.3 million (2024), whereas its average is -$44.1 million.
  • Its Net Income has fluctuated over the past 5 years, first soared by 65760.0% in 2021, then crashed by 493243.24% in 2023.
  • Over the past 5 years, Emergent BioSolutions' Net Income (Quarter) stood at $177.9 million in 2021, then plummeted by 137.66% to -$67.0 million in 2022, then increased by 26.12% to -$49.5 million in 2023, then surged by 36.77% to -$31.3 million in 2024, then soared by 263.58% to $51.2 million in 2025.
  • Its Net Income was $51.2 million in Q3 2025, compared to -$12.0 million in Q2 2025 and $68.0 million in Q1 2025.